Thalidomide as treatment for digestive tract angiodysplasias

Netherlands Journal of Medicine

Volumn 64, Issue 11, 2006, Pages 425-428

  Heidt, J ^a   Langers, A M J ^b   van der Meer, F J M ^b   Brouwer, R E ^a  

^a MCH Antoniushove ^*  (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiodysplasias; Gastrointestinal bleeding; Thalidomide

Indexed keywords

BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; HEMOGLOBIN; THALIDOMIDE; TRANEXAMIC ACID;

AGED; ANGIODYSPLASIA; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CAPSULE ENDOSCOPY; CASE REPORT; CLINICAL PROTOCOL; DIGESTIVE SYSTEM DISEASE; DISEASE SEVERITY; DRUG WITHDRAWAL; FECES; FECES ANALYSIS; HOSPITAL ADMISSION; HUMAN; MALE; MELENA; MONOTHERAPY; RECURRENT DISEASE; SMALL INTESTINE; TREATMENT OUTCOME; VON WILLEBRAND DISEASE;

AGED, 80 AND OVER; ANGIODYSPLASIA; GASTROINTESTINAL DISEASES; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MELENA; RECURRENCE; THALIDOMIDE; TREATMENT OUTCOME; VON WILLEBRAND DISEASE;

EID: 33845811430     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Gordon FH, Watkinson A, Hodgson H. Vascular malformation of the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2001;15:41-58.
2. Lewis BS, Kornbluth A, Waye JD. Small bowel tumours: yield of enteroscopy. Gut 1991;32:763-5.
3. Van Cutsem E, Rutgeerts P, Vantrappen G. Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet 1990;335:953-5.
4. Junquera F, Feu F, Papo M, et al. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology 2001:121;1073-9.
5. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961;ii:1358.
6. Lenz W. Thalidomide and congenital abnormalities. Lancet 1962;i:45.
7. Lenz W. A short history of thalidomide embryopathy. Teratology 1988;38:203-15.
8. Wu KL, Schaafsma MR, Lokhorst HM, Wijermans PW, van der Holt B, Sonneveld P. Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients revealed an antitumour effect in 45%. Ned Tijdschr Geneeskd 2002;146(31):1445-8.
9. Sheskin J. Thalidomide in treatment of lepra reaction. Clin Pharmacol Ther 1965;6:303-6.
10. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:443-50.
11. Wood PMD, Proctor SJ. The potential use of thalidomide in the therapy of graft-versus-host disease - a review of clinical and laboratory information. Leuk Res 1990;14:395-9.
12. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open label trial. Gastroenterology 1999;117:1271-7.
13. Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronic active, steroid dependent Crohn's disease. Gastroenterology 1999;117:1278-87.
14. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomised, double-blind, placebo-controlled clinical trial. AIDS 1996;10:1501-7.
15. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious diseases AIDS Clinical Trials Group. N Engl J Med 1997;336:1487-93.
16. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000;18:708-15.
17. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
18. Raje N, Anderson K. Thalidomide - a revival story. N Engl J Med 1993;341:1606-8.
19. Bauditz J, Wedel S, Lochs H. Thalidomide reduces TNF-α and interleukin 12 production in patients with chronic active Crohn's disease. Gut 2002;2:196-200.
20. Franks ME, MacPherson GR, Figg WD. Thalidomide, a review. Lancet 2004;363:1802-11.
21. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994:91(9):4082-5.
22. Li X, Liu X, Wang J, et al. Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res 2003;23(3B):2481-7.
23. Junquera F, Saperas E, de Torres I, et al. Increased expression of angiogenic factors in human colonic angiodysplasia. Am J Gastroenterol 1999;94:1070-6.
24. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
25. Bauditz J, Schachschal G, Wedel S, Lochs H. Thalidomide for treatment of severe intestinal bleeding. Gut 2004;53:609-12.
26. Heyde EC. Gastrointestinal bleeding in aortic stenosis. N Engl J Med 1958;259:196.
27. Love JW, Jahnke EJ, Zacharias D, Davidson WA, Kidder WR, Luan LL. Calcific aortic stenosis and gastrointestinal bleeding. N Engl J Med 1980;302(17):968.
28. Drenth JP, Nagengast FM. Aortic stenosis and intestinal blood loss from angiodysplasia: valve replacement is a therapeutic option. Ned Tijdschr Geneeskd 2000;144(47):2237-40.
29. Bhutani MS, Gupta SC, Markert RJ, Barde CJ, Donese R, Gopalswamy N. A prospective controlled evaluation of endoscopic detection of angiodysplasia and its association with aortic valve disease. Gastrointest Endosc 1995;42(5):398-402.
30. Noach LA, Mathus-Vliegen EM, Dunning AJ, Tytgat GN. Angiodysplasias in the digestive tract and associated cardiovascular diseases. Ned Tijdschr Geneeskd 1989;133(34):1696-700.
31. Warkentin TE, Moore JC, Morgan DG. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand's disease the link? Lancet 1992;340(8810):35-7.
32. Warkentin TE, Moore JC, Morgan DG. Gastrointestinal angiodysplasia and aortic stenosis. N Engl J Med 2002;347(11):858-9.
33. Shurafa M, Kamboj G. Thalidomide for the treatment of bleeding angiodysplasias. Am J Gastroenterol 2003;98(1):221-2.
34. Hirri HM, Green PJ, Lindsay J. Von Willebrand's disease and angiodysplasia treated with thalidomide. Haemophilia 2006 May;12(3):285-6.
35. Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons-O'Brien E, Vogelsang G. Thalidomide-induced neuropathy. Neurology 2002;59:1872-5.
36. Molloy FM, Floeter MK, Syed NA, et al. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve 2001;24:1050-7.
37. Maier SK, Hammond JM. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome. Ann Pharmacother 2006;40(2):286-9.
38. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106(13):4050-3.